Author

Chun-Peng Pai

Case Comprehensive Cancer CenterPrimary ORCID profile (0009-0007-4306-1590 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Chun-Peng PaiiD1 paper · Case Western Reserve University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Chen WuiD· 1 shared Donald Patrick McDonnelliD· 1 shared Han Wang· 1 shared Hung‐Ying KaoiD· 1 shared Jiangan Yue· 1 shared Kristen L. Weber-BonkiD· 1 shared Lisheng GengiD· 1 shared Qianqian Wang· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chen WuORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Mitoxantrone inhibits and downregulates ERα through binding at the DBD-LBD interface

Han Wang, Yuxuan Luo, Sandeep Artham, Qianqian Wang, Yi Peng, Zixi Yun, Xinyue Li, Chen Wu, Zhenghao Liu, Kristen L. Weber-Bonk, Chun-Peng Pai, Yuan Cao, Jiangan Yue, Sunghee Park, Ruth A. Keri, , Sichun Yang

This study shows mitoxantrone inhibits ERα by binding at the DBD-LBD interface, causing conformational changes and degradation, and effectively targets ER mutations resistant to current therapies.

Molecular Cancer Therapeutics · Sep 10, 2025Peer-reviewedCancer Biology